Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

NCT01829477 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

33

Enrollment

INDUSTRY

Sponsor class

Stopped Due to potential concerns about liver safety (See Detailed Description)

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: TAK-875
DRUG: TAK-875 Placebo
DRUG: Glimepiride

Sponsor

Takeda